Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Trial of SHR-1701 Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Subjects With Advanced/Metastatic Pancreatic Cancer

NCT04624217 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT04624217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Trial of SHR-1701 Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Subjects With Advanced/Metastatic Pancreatic Cancer
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 24, 2020
Completion date
February 8, 2023
Enrollment
56 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer